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Background: Chronic cerebrospinal venous insufficiency (CCSVI) treatment is an unproven intervention aimed
at relieving some of the symptoms of multiple sclerosis (MS). Despite limited evidence of the efficacy and safety
of this intervention, Canadians diagnosed with MS have been traveling abroad to access this procedure as it is
not available domestically outside of limited clinical trials. This paper discusses the experiences of Canadians with
MS seeking CCSVI treatment abroad.
Methods: This paper presents a secondary analysis of 15 interviews with participants who had gone abroad for
CCSVI treatment. Interviews were conducted over the phone between October 2012 and December 2012. All
interviews were digitally recorded and transcribed verbatim. Transcripts were hand coded for: 1) why CCSVI
treatment was sought and where it was obtained; 2) the role of having hope for a cure in seeking CCSVI; 3)
the impact of MS on everyday life; and 4) the role other people played in the decision to go abroad.
Results: The authors identified loss of faith, hope, and trust as themes emerging from the transcripts. The
participants experienced a loss of faith with the Canadian health system and especially the neurologists who
were responsible for their care and the classification of MS as a neurological disease. Access to CCSVI treatment
abroad generated hope in these participants, but they were cautious in their expectations, focusing on symptom
management rather than a cure. Trust in their caregivers abroad was generated through the recommendations
of other MS sufferers and the credentials of their caregivers abroad.
Conclusions: By deciding to seek an unproven intervention abroad, these individuals took on responsibility for
their care from the Canadian health system. While evidence of the efficacy of CCSVI treatment is limited, the
participants felt that they were making a rational care decision, focusing on the empowerment and renewed
hope generated by seeking this intervention. Health professionals and policy makers globally should consider
the causes of loss of faith in their domestic care systems and balance the benefits of empowerment and renewed
hope against concerns that unproven interventions may create new health risks.
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Canadians have long traveled abroad for medical care as
medical tourists [1]. While many of these individuals
travel abroad to avoid wait times for necessary care or to
obtain lower prices for elective procedures, others seek
procedures not available domestically because of a lack
of capacity or because they have not been approved for
domestic use. A wide range of unproven medical interven-
tions and equipment draw Canadians abroad for care,
including stem cell interventions and new forms of hip
replacements [1,2]. Recently, some Canadians’ interest in
obtaining care abroad has been spurred by an unproven
intervention for multiple sclerosis (MS) known as chronic
cerebrospinal venous insufficiency (CCSVI) treatment.
Following a prolonged debate as to whether the Canadian
government would fund access to this intervention, a
negative decision was reached, effectively blocking domes-
tic access to CCSVI. As a result, some Canadians with MS
have decided to travel abroad in order to access this care,
thus circumventing restrictions placed by their domestic
government [3].
MS is a disorder of the central nervous system with
undetermined causes. It leads to damage to the central
nervous system through an autoimmune response, result-
ing in a variety of symptoms including vertigo and changes
in vision, sensory sensation, energy levels, and motor func-
tion [4]. In 2009, a new theory of the pathology of MS was
presented by Paolo Zamboni who suggested abnormal cra-
nial venous outflow or CCSVI may be present in all people
who have MS [5]. According to Zamboni’s theory, this
abnormal outflow is responsible for at least some of the
symptoms associated with MS [5]. Treatment for this
proposed condition is available, involving expanding the
blocked or narrowed vein (typically the jugular) using
venoplasty or stents [6].
Since 2009, researchers have investigated the suggested
association between CCSVI and MS. There have been no
subsequent reported results with the high correlation of
100% seen in the initial Zamboni study. A cross-sectional
study by Zivadinov et al. [7] found that 56% of MS partici-
pants qualified for a CCSVI diagnosis while prevalence in
healthy persons was 22% and persons with other neuro-
logical disorders had 42% prevalence with CCSVI. How-
ever, no randomized control trials have provided evidence
of the efficacy of CCSVI treatment for the relief of the
symptoms of MS [8-13]. Most recently, studies of 199 and
177 individuals with MS respectively failed to find a con-
nection between CCSVI and MS [9,14].
Canada has one of the highest incidences of MS in the
world, with over 95,000 cases diagnosed in 2013 [15,16].
Despite the lack of evidence linking CCSVI treatment
with symptom relief in individuals with MS, there has
been considerable pressure within Canada to make this
intervention available to interested individuals [17,18].Canada’s public health care system, which is administered
separately by each province/territory as per the national
Canada Health Act, provides medically necessary care to
citizens through interventions determined to be efficacious
and cost effective [19]. Treatment of CCSVI for Canadians
with MS has not been approved in the public system
due to the lack of clear evidence of efficacy, though some
Canadian provinces and the federal government have
funded clinical trial participation for their residents both in
Canada and abroad [20]. The Canada Health Act heavily
restricts the provision of private medical care in the
country, meaning that CCSVI treatment cannot be offered
domestically for Canadians wishing to pay privately for
such care. While federal and provincial funding for clinical
trials on CCSVI has been approved, these trials currently
provide very limited opportunities for Canadians to re-
ceive CCSVI treatment domestically [18]. As a result,
Canadians with MS wishing to access CCSVI treatment
are left with the options of seeking to become one of the
few individuals allowed to enroll in clinical trials on CCSVI
treatment or privately seeking interventions outside of the
country as medical tourists.
Those Canadians who choose to travel abroad to ob-
tain CCSVI treatment must arrange for this intervention
on their own and pay for it out-of-pocket [21,22]. In some
cases, individuals have reported symptom relief following
CCSVI treatment [23]. In the province of British Columbia,
for example, half of those persons participating in a registry
for CCSVI treatment recipients reported symptom relief
[24]. This symptom relief is often not permanent, however,
requiring individuals to travel abroad repeatedly for CCSVI
treatment [24]. Other Canadians who have already gone
abroad for treatment have faced complications and difficul-
ties obtaining follow up care for their MS from their regu-
lar health care providers [25]. In extreme cases, obtaining
CCSVI treatment abroad has led to the death of Canadians.
For example, one Canadian man died following CCSVI
treatment received in Costa Rica after experiencing diffi-
culty obtaining treatment for complications following the
procedure upon return home to Canada [26]. A second
Canadian patient who received CCSVI treatment in the
United States died from complications from the procedure
as well [26]. These setbacks have led to charges that the
Canadian media engaged in ‘hope mongering’ that has
encouraged people with MS to engage in a risky and un-
proved therapy [27]. Nonetheless, MS advocacy groups
have become highly organized through social media and
have been successful in influencing the Canadian political
debate on the funding of CCSVI treatment in Canada [3].
Despite the lack of clear evidence connecting MS and
CCSVI, Canadians continue to advocate for domestic ac-
cess to CCSVI treatment and to travel abroad for CCSVI
treatment in the hope that it will at least temporarily re-
lieve some of the symptoms of their disease.
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structured interviews with Canadians with MS who
sought CCSVI treatment abroad. We specifically exam-
ine issues central to their decisions to go abroad for this
intervention. This paper serves to shed light on the ex-
periences of Canadians who have received CCSVI treat-
ment as medical tourists and will serve to augment
research on the global health services practice of medical
tourism.
Methods
This analysis is part of a larger study aiming to develop
an informational tool for better informing Canadians
about ethical concerns related to medical tourism [28].
As part of this study interviews were conducted with
Canadians who had previously gone abroad as medical
tourists to examine their decision-making processes and
the usefulness of such a tool. During the initial analysis
of these interviews, distinct perspectives emerged on
the decision-making process from medical tourists diag-
nosed with MS and traveling abroad for CCSVI (n = 15)
compared to those traveling for other procedures (n = 9)
(e.g., gastrectomy, cholecystectomy, lumbar disc replace-
ment). This paper presents a secondary analysis that
examines the cases of only those 15 interviewees who
had gone abroad for CCSVI treatment. 9 participants
identified as female and 6 as male. Their age ranged from
28 to 65 with a median age of 50. Participant income
included less than CDN$30,000 (n = 3); $30,000-50,000
(n = 4); $50,000-80,000 (n = 4); and more than $80,000
(n = 3) with one participant not responding. They had
completed high school (n = 1), taken some college courses
(n = 7), completed a secondary degree (n = 5), or taken
some graduate courses (n = 2). These individuals lived in 5
different Canadian provinces and went abroad to Bulgaria,
Egypt, India, Mexico, Poland, and the United States
between 2010 and 2012 for CCSVI treatment.
Recruitment
Following receipt of ethical approval from the Office of
Research Ethics at Simon Fraser University, we recruited
former Canadian medical tourists to participate in these
interviews using: 1) advertisement on Craigslist; 2) ad-
vertisement in a Vancouver-based newspaper; 3) posting
invitations to participate in online medical tourism fora;
and 4) snowball sampling through interview participant
networks and past research participant networks. Inter-
ested individuals were asked to contact either a toll-free
number or email address for more information about
the study and assessment of eligibility. Eligibility was as-
sessed according to four inclusion criteria: 1) 18 years or
older at the time of going abroad for medical care; 2) a
holder of a provincial/territorial medical card; 3) some-
one who had accessed a surgical procedure outside ofCanada that was neither a transplantation nor a repro-
ductive surgery (as these procedures often involve third
parties and raise distinct ethical issues); and 4) someone
who paid privately for the medical procedure sought
abroad. Those deemed eligible for participation were
provided with a consent form to read and sign before
beginning the interview. Verbal confirmation of informed
consent was also obtained at the beginning of the inter-
view and participants were assured of their anonymity.
Data collection
Interviews were conducted between October 2012 and
December 2012. On-going recruitment occurred during
these months with the intention of completing as many
interviews as possible before ceasing recruitment at the
end of this time period. Interviews lasted on average
45 minutes, with the shortest lasting approximately
thirty minutes and the longest lasting approximately one
hour and a half. This range in interview times is due to
their semi-structured nature, wherein a standard guide
for interview questions was used but participants were
also invited to discuss ideas that were not otherwise
asked that may provide meaningful insight to a broader
understanding of the topic at hand [29]. The interview
guide contained questions organized into four sections:
basic background information, including demographics,
general health, and past travel experiences; participants’
general decision-making behaviours; participants’ experi-
ences as a medical tourist; and participant feedback on
the informational tool.
All interviews were conducted over the phone, a
technique that enabled interviews to be completed
with Canadians from across the country. While phone in-
terviews are unable to capture participants’ body language,
they are increasingly common due to their cost effective-
ness [30].
Data analysis
All interviews were digitally recorded and transcribed
verbatim. Transcripts of interviews conducted with par-
ticipants who had gone abroad for CCSVI treatment
were hand coded for four broad categories identified
through transcript review by the authors: 1) why CCSVI
treatment was sought and where it was obtained; 2) the
role of having hope for a cure in seeking CCSVI; 3) the
impact of MS on everyday life; and 4) the role other
people played in the decision to go abroad. Coding ex-
tracts were next independently reviewed by all authors.
Following review of these extracts, all authors met to
discuss emerging analytic themes, paying particular atten-
tion to patterns and outliers in the discussions. During
this meeting, consensus was reached on three themes cen-
tral to participants' decisions to go abroad and the scope
of each of these themes was established. In this paper we
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depth of these themes. Thematic analysis necessitates
identifying themes based on patterns in a qualitative data-
set and comparing these emerging themes to established
findings in existing literature to help identify their import-
ance or novelty [29].
Following identification of these themes, the first and
fourth authors reviewed the full transcripts again to ensure
that all relevant data had been captured. The first author
then selected the quotes that best illustrated the nature of
these themes. All authors independently reviewed these
selected quotes and met again to confirm their inter-
pretation along with the scope of each theme and also to
discuss the findings as they relate to the existing literatures
on medical tourism, patient decision-making, and health
care rationing. This study adheres to the RATS guidelines
on qualitative research.
Results
Three themes commonly characterized the journeys of
Canadians with MS who decided to leave the country in
search of CCSVI therapy abroad. These individuals first
experienced a loss of faith in the Canadian health system
by virtue of their frustration with domestic health care
providers and health system administrators who would
not accommodate their desires to access unproven inter-
ventions at home. Following this loss of faith, these indi-
viduals nurtured hope that access to CCSVI treatment
abroad could eliminate or lessen some of their symptoms
of MS, though they were generally measured in their
expectations. Once hope for better quality of life through
travel abroad was established they finally embarked on
their trips abroad, forming trust and through it confidence
in the credentials and personalized service of their care-
givers. Faith, hope, and trust were thus central to their de-
cisions to ultimately go abroad and seek CCSVI treatment
in another country as medical tourists. In the sub-sections
that follow we examine these three thematic findings
in depth.
Losing faith
The participants described a loss of faith with different
aspects of the Canadian health system due to their inabil-
ity to access CCSVI treatment at home. They felt their
diagnosis with MS marked them out as different from the
rest of the population and subject to inferior treatment.
One participant referred to having the “scarlet letters of
MS attached to my medical file.” Whereas the participants
felt that other Canadians were able to access vascular
treatments similar to those used for CCSVI for conditions
not related to MS, their doctors told them that they could
not apply these same interventions to treat their MS. As a
result, one participant “didn’t have any hope” after his
doctors explained that they “could lose their job if theyeven helped me because I have MS.” In this way, people
with MS felt singled out in the public health care system:
“you know they do this procedure on everyone else in
Canada but they won’t treat MS patients. Anybody that’s
previously labeled, we can’t have it.” This experience left
one participant with the attitude that, “once you’re labeled
with MS, good luck [with accessing care].” As a result, the
participants felt that their treatment by the Canadian
health care system was unfair when compared to the
situation of other, similarly situated persons with vascular
diseases not related to MS.
Blame for feelings of unfair treatment by the Canadian
medical system was largely targeted at neurologists who
serve as gatekeepers to specialized treatment. As a result
of the perceived resistance of neurologists to the vascular-
based CCSVI treatment, one participant voiced that he
would not trust a neurologist “as far as I could throw one”
and another mentioned “rage and a lot of anger” targeted
at neurologists. This antagonism toward neurological spe-
cialists complicated care within the Canadian system for
the participants. For example, one participant mentioned
not visiting his neurologist before seeking care abroad
because all “neurologists were against CCSVI.” This disen-
gagement took place following CCSVI treatment abroad
as well. One patient said that upon returning to Canada
following treatment abroad, his neurologist “hasn’t talked
to me, he hasn’t tried to contact me and I don’t see any
reason why I should go see the man.” Some participants
reported tension between the views of their family doctors
and neurologists over the potential benefits of CCSVI
treatment that created frustration. As a result, one partici-
pant described her experience of feeling stymied by her
neurologist even when her family doctor was supportive
of her accessing CCSVI: “[the family doctor’s] hands are
tied. Because once again a neurologist has domain over my
disease. Not even I have domain over my disease…it’s in
the hands of the neurologists and that’s not fair.” Partici-
pants were particularly frustrated by their loss of faith in
the Canadian medical establishment as they saw CCSVI
treatment as a chance to address the root causes of MS
rather than continue a cycle of symptom management.
Connected to this loss of faith in Canadian medical
specialists, many participants felt a loss of faith in the
Canadian health system as a whole and felt pushed into
the health systems of other countries as medical tourists.
This loss of faith took the form of a violation of the expec-
tation that the Canadian health system would be res-
ponsive to their perceived health needs given a lifetime of
supporting this system through their taxes and viewing
the health system as an important part of their Canadian
identity. For some, this experience led to feelings of aban-
donment, with one participant saying that: “when you’ve
got MS you’re on your own.” Another noted that he felt as
though “my country abandoned me,” saying that “there
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here to talk about CCSVI please leave.” In one case, the
lack of access to CCSVI at home led a participant to de-
velop an adversarial reaction toward Canadians generally:
“your fellow Canadians would not let you have it at home.
So you’re going elsewhere, that’s about all you need to know
about your fellow Canadians. …at that point they are
adversaries, they’re not working with you, they’re standing
in your way.” In another case, the experience of having to
become a medical tourist was described as “a slap in the
face” by a Canadian health system in which she had had
faith throughout her adult life. The financial costs of going
abroad for care were another source of anger toward the
Canadian health care system that would have paid for the
intervention were it offered domestically in the public
system: “I was very upset and disappointed that I had to
basically spend $10,000…It just doesn’t make any sense
and it’s not fair.” From the perspective of these partici-
pants, the Canadian health system should have provided
access to an intervention that they hoped could address
the root causes of MS at no additional cost to them. The
refusal of specialists, health system administrators, and
government officials to provide access to this intervention
forced them to go abroad for care at significant personal
cost, resulting in an overall loss of faith in the Canadian
health system in addition to specific health care providers.
Nurturing hope
The participants regularly described their decision to
travel abroad for an unproven medical intervention as
driven by a range of emotions, but particularly as a re-
sult of hope for relief of the progressive decline in their
health brought on by MS. As one participant described
it, CCSVI was “our only hope at that time” and the care
offered by local doctors did not provide “a lot of inspir-
ation to carry on.” Hope for better health from CCSVI
treatment was also discussed in terms of providing “posi-
tivity” and for bringing about a sense of excitement. For
example, a participant described how hope combined
with excitement shaped her interactions with the doctor
she saw while abroad. This doctor “didn’t make any, any
real promises he just had as much hope as I did and that
was, it was nice, it was exciting, more than I had had in
a long time.” While hope drove many to seek CCSVI
treatment abroad, contrasting emotions such as fear were
experienced as well, with one participant explaining that
there was also “the fear of the unknown.” Despite some
fear at the prospect of traveling abroad to access an un-
proven medical intervention, their new hope of arresting
the progression of their MS was the dominant emotion
driving participants’ decisions to become medical tourists.
Worsening health and the loss of quality of life brought
on by MS was a significant factor driving participants
abroad. This loss of quality of life was the key motivationfor some who reported being “willing to do anything to
have the quality of life that you want.” Given the progres-
sive loss of quality of life and the perceived lack of effect-
ive treatments within Canada, seeking CCSVI treatment
abroad was felt by some to be the only option for treat-
ment, even if success was far from guaranteed. Despite
this lack of guaranteed success, doing nothing was not
seen as an option. For these participants, staying in
Canada would be equivalent to accepting as permanent
the loss of function from MS, and so any response was
desirable. As one participant put it: “I knew what was
going to happen to me if I did nothing. And so I was going
to do something.” For others, not seeking treatment abroad
would be the same as accepting death, thus making taking
a chance on CCSVI treatment “a rational choice.” Due to
the progressive nature of some forms of MS, many par-
ticipants felt pressure to act quickly rather than wait for
the possibility that CCSVI treatment would eventually be
offered domestically. As one noted, “time works against
you when you have MS, every day there is a little piece of
you that seems to die off.” The natural progress of their
disease and restrictions on access to CCSVI treatment at
home, then, made the decision to go abroad for care seem
clear and fully rational.
For the most part, the participants did not believe that
they would be cured of MS as a result of undergoing
CCSVI treatment abroad. Their measured hope was in
some cases informed by the cautions of the physician
providing the intervention. In one case, an international
physician told a patient: ‘don’t go in expecting miracles.
This is not a cure, this is symptom management.’ In
another case, a patient did not receive the symptom re-
lief that she most desired, but still saw an improvement
in other areas. As a result, she reported that her “overall
well-being has improved.” For another participant, symp-
tom relief did not need to be permanent in order for the
procedure to be deemed worthwhile: “if there was a
chance that a person could alleviate the symptoms for
even a little period of time. It’s worth it.” Some partici-
pants had their expectations around CCSVI treatment
tempered by past experiences with unproven interven-
tions, having previously been told of “quack remedies” or
actually spending money on “trying for hope.”
Forming trust
While loss of faith in the Canadian health system and
hope for improved health both motivated participants to
travel abroad for care, they had to develop some form of
trust in the specific clinics and physicians in the destin-
ation countries they visited. For some, the decision to go
abroad for care was supported in part by peer support
networks that participants had built up with others seeking,
or who had sought already, CCSVI treatment abroad.
Distrust of neurologists and the MS Society led one
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people with MS because it “is our disease” and they are
“banding together.” Within online groups, the fact that
people who had already gone abroad had “firsthand
knowledge” of the intervention was seen as important.
Online groups on Facebook became (and continue to be)
trusted sources of information for some participants, with
one noting that “we were able to go to this [Facebook]
group and find all of these good places and bad places to
go to get it done” and another likening Facebook to the
“underground railroad.” Many participants found confi-
dence in their own research, trusting themselves to deter-
mine which sources of information were most reliable.
One noted how seriously she had researched CCSVI treat-
ment and the clinics abroad, saying: “I don’t just go off on
a song and a prayer, I actually research things and then I
make a decision.” In all of these cases, the participants we
spoke with became heavily reliant on their own networks,
both face-to-face and virtual, and online information when
determining where to travel for care and which physicians
and clinics to place their trust in.
While most participants had lost faith in the Canadian
medical system and especially the neurologists treating
them, the professionalism and credentials of their physi-
cians abroad remained an important element in building
trust in the care they would receive. This process of trust
building took place in a context where several participants
discussed having read media reports of Canadians suffer-
ing significant negative health impacts from accessing
CCSVI treatment abroad. In one case, a participant noted
that her physician abroad was “actively researching” new
MS treatments and saved the life of another patient while
she was in the facility. Another took pictures of the pla-
ques and credentials on the wall of the waiting room in
the facility, noting “a huge wall full of certificates.” Many
participants felt able to assess the credentials of their
physicians abroad prior to travel, often with assistance
from online information and their support networks.
Phrases used to assess these credentials included “board
certified” and “experts,” with one participant noting that
she “trusted the qualifications that they said these
people had.” The opinions of physicians back home also
served to instill confidence in physicians abroad. In one
case, a participant asked her regular family physician
about the credentials of her prospective physicians in
India and was told that they would have been educated
in the United Kingdom and so their training would be
similar to that of Canadian doctors. The ability to commu-
nicate with physicians abroad prior to booking CCSVI
treatment was also important to building confidence in
the quality of care they would receive, and trust in these
physicians. After she spoke with her international phys-
ician over the phone, one participant noted that: “I felt
very, very confident.” However, for a minority of theseparticipants, trust in professionalism was more of a leap of
faith based on “faith and trust” that the physician was
looking out for their best interests rather than being based
on degrees and other qualifications.
The interviews revealed that participants not only
needed to trust the physicians from whom they received
CCSVI treatment, but also that they needed to form a
certain degree of trust that their health and safety were
secure in the destination country and clinic as well. In
some cases, participants were already familiar with the
international health systems being accessed, with one
choosing a destination based on having been born there
and having other family connections to that country.
Another participant felt comfortable traveling to Poland
as that country had joined the European Union and
adopted Western medical standards, which he trusted as
a quality indicator. Some participants were initially con-
cerned about the quality of care and facilities abroad.
One participant traveling to Bulgaria was reassured that
the hospital had been built and funded by Japan. Another
participant had heard “weird things about Mexico” and
was worried that she would find “a dirty stable” instead of
a hospital. She was ultimately reassured by the appearance
of cleanliness of the facility and that “nurses down there,
they’re dressed like nurses with white caps on and starch
white gowns.” In other cases, participants felt that the
standard of care they received abroad was superior to that
experienced in Canada, which enhanced their trust in
clinics abroad. One patient noted her physician abroad
“spent probably forty-five minutes to an hour on the phone
with me. I don’t even get forty-five minutes to an hour with
my doctor here in Canada.”
Discussion
The findings shared above show that a number of com-
plex factors surrounding losing faith, nurturing hope,
and forming trust informed participants’ decisions to go
abroad for CCSVI treatment, including the country they
visited, the clinic they sought care in, and the physician
who provided this care. Participants felt abandoned by
the Canadian health care system as well as their neuro-
logists, which prompted them to lose faith in both the
system as well as specific providers. In light of this loss of
faith and driven by the desire for symptom relief, they felt
as though they had no other option but to go abroad for
treatment. Overall, hope for an improved quality of life
drove participants’ decisions to travel abroad for the un-
proven CCSVI procedure. This was not hope disconnected
from reason, however, and many were modest in their
expectations and cognizant that improved quality of life
was not guaranteed. For some, simply trying to better
manage a particular symptom was enough of a motivation
to go abroad. Despite their loss of faith in medical profes-
sionals at home, the credentials and opinions of medical
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their health and safety to CCSVI treatment. Whereas they
had lost faith in Canadian specialists, they were willing to
place trust in foreign medical providers, often aided by the
experiences and perspectives of their peers and the famil-
iarity of the facilities abroad. These findings raise a num-
ber of important issues around the shifting of blame and
enactment of personal responsibility for care as well as the
balance between hope and rational choice that we exam-
ine in this section.
Shifting blame and personal responsibility
Characteristic of these interviews were feelings of neg-
lect and abandonment by the Canadian health system,
specialists within that system, and even the Canadian
public. These participants felt extreme frustration that a
procedure that was being offered in other countries was
not being offered in Canada. Similar frustration has been
reported by Canadians who have gone abroad as medical
tourists for orthopaedic procedures that are not readily
available at home [31]. In the current study, this frustra-
tion was fueled by the fact that refusal to offer CCSVI
treatment was not a result of a lack of expertise but
because of an active choice by political representatives
to block access to this intervention. This frustration was
exhibited despite the lack of proven efficacy of CCSVI
treatment in addressing the causes of MS and the fact
that the government of Canada was not alone in not
funding access to and warning against choosing to
undergo CCSVI treatment [9-14]. For many, this decision
by the government to block access to CCSVI treatment
was experienced as a loss of agency – where agency is the
state of being that enables us to have the ability and flexi-
bility to problem solve [32]. This reality thrust the partici-
pants into becoming extremely active proponents of their
own health, seeking out new interventions for MS on their
own, communicating with similar others in person and
through online communities, and sometimes even advo-
cating for increased funding for research and access to
care. A number of studies focused on the lived experience
of chronic illness have documented similar individual and
collective activities being undertaken by those managing
chronic illnesses such as MS [33,34]. It is not surprising,
then, that many of these participants were unwilling to
abandon their active engagement with managing their dis-
ease, choosing instead to seek access to CCSVI treatment
abroad even if it required significant personal risk, incon-
venience, and financial cost.
Diagnosis with MS is an extremely emotionally charged
event [35]. While many of the participants we spoke with
experienced feelings of anger and resentment as a result
of their diagnosis, they remained active in seeking, if not a
cure for their disease, at least access to the latest interven-
tions that could enhance the quality of their lives. As aresult of their inability to access CCSVI treatment within
Canada, some of these feelings of anger and resentment
shifted from their disease to the Canadian health system.
Other research has shown that the development of such
resentment leads Canadians to view their engagement in
medical tourism as ethically defensible [36]. In many cases
participants sought specific targets for their frustration,
including neurologists who sought to keep MS defined
as a neurological rather than vascular condition and a
Canadian public who simply did not care about their
needs. As a result, many of these participants exhibited
an ‘us vs. them’ attitude, alienating them from their domes-
tic health care system. Similar findings have been reported
regarding the health care experiences of individuals diag-
nosed with contested chronic illnesses such as fibromyalgia
syndrome or myalgic encephalomyelitis, wherein such indi-
viduals have been made to feel at odds with the Canadian
health system [37,38]. In the current study, this feeling of
alienation from the health system was heightened by par-
ticipants’ belief, gained from active research about their
disease and CCSVI treatment, and bolstered by an active
online community of fellow sufferers, that a treatment for
their disease existed, if only their government and health
system administrators would stop actively blocking them
from accessing it at home.
As a result of their decision to seek care abroad, par-
ticipants took control of their own health from a system
that uses gatekeepers to control access to care and
placed responsibility for their health into their own
hands. In many senses, this shift was empowering, allow-
ing participants to choose not only what procedures they
would be given, but by what doctor, in what facility and
country, and at what time. In a similar manner, the global
medical tourism industry has been framed by some as
enabling patient empowerment as it facilitates choice and
access, though at a cost [39]. Online communities of
people with MS aided in this process of empowerment by
exchanging tips about the best physicians, which facilities
had the shortest wait times for care, and which countries
were becoming new destinations for Canadians seeking
CCSVI treatment. The downside of this personal em-
powerment, however, was a shift in responsibility for any
negative health consequences to the participants them-
selves as a result of seeking care abroad privately, and
often without the support of their regular physicians at
home. The Canadian media contains many stories of
people who have obtained CCSVI treatment abroad re-
turning to Canada having negative health consequences
and being denied care by domestic physicians [25,40,41].
Many of the participants we interviewed specifically cited
these stories and were aware that by going abroad for care
they were potentially endangering their future access to
follow-up or emergency care at home. More importantly,
they saw their decision to go abroad for care as creating a
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were willing to take on this responsibility speaks to their
drive to improve their quality of life, frustration with the
Canadian system, and desperation for gaining access to
new care options.
Hope and rational choice
The findings illustrate the distinction between partici-
pants’ hope and expectations when undergoing CCSVI
treatment. Here hope can be understood as an individual’s
assessment of the most desirable outcomes while expec-
tations can be understood as an individual’s probability-
driven assessment of the most likely outcomes from
medical treatment. Researchers have highlighted the the-
rapeutic importance for health care providers to balance
fostering hope and providing realistic expectations to
patients [42]. Finding this balance can be challenging as
these concepts are often conflated. People may understand
that the desirable outcomes differ from the probable out-
comes, yet hope persists as a coping mechanism. In the
current study, the participants’ understanding of MS as
being incurable and degenerative appeared to inform the
development of hope as a coping mechanism, which
played a significant role in leading them to consider going
abroad for CCSVI treatment. Hope is also both shaped by
and shapes one’s agency [32]. Participants’ discussions of
trip planning demonstrate an example of this mutually
reinforcing process as the agency they exerted in traveling
abroad for CCSVI therapy fostered hope for symptom-
relief, while hope for symptom-relief fostered increased
agency to pursue goals that were not merely determined
by the expected health outcomes.
Contrary to common assumptions that individuals en-
gage in unproven procedures due to a lack of awareness
of likely procedure outcomes or potential risks [42], the
findings shared here show that people traveling abroad
for unproven procedures can embark on a journey that
places these risks within a context of hope and even possi-
bility. As has been shown in research focused on people
traveling abroad for unproven stem cell therapies, this
journey is thus undertaken within the context of consider-
ations of both the risks and possibilities that shape indi-
vidual hope that ultimately inform decisions in medical
tourism [43]. The findings of the current study demon-
strate the ability for this journey to bring about excitement
and feelings of empowerment that shape individual’s con-
siderations of risks and possible outcomes. Although there
is concern that a strong sense of hope may push people
to overlook health and safety risks when making health
decisions [44], there is also recognition that the em-
powerment, optimism, and motivation fostered through
hope can provide important therapeutic benefits for
people coping with chronic illness [32,43]. Although the
current study did not assess the therapeutic benefits ofthe hope expressed by the participants, the findings do
point to a need to better understand the role and bene-
fits of hope in motivating medical tourists’ journeys
abroad in order to complement the existing significant
research focused on risk (e.g., [45-47]).
The findings demonstrate that participants’ hope was
tempered with rational expectations about their CCSVI
treatment outcomes. Expectations of major improvements
in health or wellbeing were often tempered by physician
advice, the experiences of others, or negative past experi-
ences. Instead, improvements in fatigue, bladder control,
or short-term changes in general wellbeing were expec-
tations deemed sufficient enough to justify their choice of
intervention. Whether these outcomes would have been
identified as indicators of success prior to receiving the
intervention, or are a reflection of individuals’ desire to
attribute success to CCSVI treatment in the presence of
negligible changes in health or wellbeing, is a research
question beyond the scope of our study. However, given
that all participants perceived their CCSVI treatments to
be successful, something that further reinforces feelings of
neglect by the Canadian system, differences between indi-
vidual and societal determinations of ‘value for money’ in
health care are important considerations to be made in
relation to providing access to unproven care.
While the therapeutic benefits of hope and experi-
ences of individuals like those who participated in this
study should play a role in decision-making around the
distribution of health resources in a public health system
such as Canada’s, it is important to stress that support-
ing the hope and empowerment of individuals cannot
alone justify utilizing limited health resources for provid-
ing access to an unproven medical intervention such as
CCSVI treatment. Putting resources into CCSVI treat-
ment would likely necessitate a loss of funding for other
interventions where evidence backs their efficacy in im-
proving health. CCSVI treatment has not been found to
be effective in treating MS nor to have a clear biological
basis for doing so. [8-14]. Those accessing CCSVI abroad
have encountered health problems as a result of this inter-
vention, meaning that the net effect of access to CCSVI
could be negative for many Canadians with MS [25,26].
Additional research is needed to better understand the
impact of CCSVI treatment on MS and other chronic
diseases, but this research is not supported by individual
patients receiving these interventions outside of clinical
trials [8]. Several jurisdictions in Canada have provided
access to these trials, granting some relief to Canadians
with MS who wish to access CCSVI treatment (through
certainly less than enough to meet demand for this
intervention) [20]. Thus, despite the experiences of the
participants in this study and benefits they may have re-
ceived as individuals by accessing CCSVI treatment abroad,
the decision within Canada not to provide access to CCSVI
Snyder et al. BMC Health Services Research 2014, 14:445 Page 9 of 10
http://www.biomedcentral.com/1472-6963/14/445treatment outside of clinical trials is very well supported
on grounds of patient safety and the efficient distribution
of health resources.
Limitations
This study helps to give voice to the decision-making and
experiences of Canadians seeking an unproven medical
intervention outside of their home country. The insights
described here provide insights for policy makers seeking
to address the loss of hope felt by these patients without
abandoning the principle that scarce public resources
should not be used to fund unproven interventions. While
these findings are relevant for other jurisdictions and
other unproven interventions, the experiences of these
patients are highly informed by the public nature of the
Canadian health system and the gatekeeper role played
by family physicians and neurological specialists in that
system, elements not shared by other health systems.
Moreover, as the study from which this paper is derived
did not set out to explore the decision-making of this
particular patient group, dimensions of their experience
may not be represented here. Additional study of the ex-
periences of individuals seeking unproven interventions
abroad is warranted.
Conclusions
The globalization of trade in health services will continue
to provide opportunities to access unproven medical inter-
ventions not available in individuals’ home countries.
Canadians seeking CCSVI treatment is a high profile ex-
ample of this practice, but they are only one of many
groups worldwide traveling abroad for unproven interven-
tions. Given the dangers associated with some of these
interventions, questions about their efficacy, and difficul-
ties accessing follow up care, it is easy to treat those pay-
ing out of pocket for these interventions as vulnerable and
even gullible individuals that should be protected from
themselves. However, the perspectives of the participants
discussed here demonstrate that the story can be much
more complex. These participants had lost faith in their
home health care system but placed trust in other health
professionals in order to nurture hope for improved well-
being. They were for the most part measured in their
expectations and felt renewed hope by seeking medical
care abroad.
These findings are important for health professionals
and policy makers in two respects. First, the loss of faith
of these participants should raise questions about what
more can be done to restore this faith in both Canadians
with MS and other groups globally. Second, while action
must be taken to protect individuals from harm from
potentially dangerous and unproven medical interven-
tions, consideration should also be given to the benefits,
including restored hope, for some individuals accessingthese interventions. While accommodating the desire to
access unproven and potentially dangerous interventions
using public funds is inappropriate, this study demon-
strates the need to better address the alienation felt by
these patients. The context of Canadians accessing CCSVI
treatment is unique, but these lessons are also relevant for
other groups accessing unproven interventions abroad.
Continued study of the perspectives of these groups will
help health professionals and policy makers to craft re-
sponses to these practices that are more responsive to the
experiences of these individuals.
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